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Summary We have previously developed a daunorubicin resistant subline of Ehrlich ascites carcinoma
(EA/DR) for studies on the reversal of daunorubicin resistance. The mean survival of untreated BALB/c mice
bearing drug sensitive parental tumour (EA/DS) is 18.4+0.6 days, mice bearing EA/DS treated with five
daily doses of 0.3mgkg-' daunorubicin greater than 60 days, and mice bearing EA/DR treated with the
same daunorubicin regimen, 21.1 + 1.4 days. We now report complete reversal of daunorubicin resistance in
EA/DR by cyclosporin A (CsA). The in vitro daunorubicin IC50, defined as that concentration of
daunorubicin required to inhibit 50% of DNA synthesis, in EA/DR was 6.7+1.15pgml-1 compared to
2.8+0.72pgml-I in EA/DS. This value was reduced to 2.8+0.52 and 2.1 +0.opgml-Idaunorubicin by 3.3
and 13.2pgml- 1 CsA respectively, P<0.05. The MST of groups of host mice bearing EA/DR either
untreated, treated with five daily doses of 0.3mgkg-' daunorubicin, treated with 80mgkg-' CsA in five
divided daily doses or treated with combined daunorubicin-CsA were 19.0+1.0, 21.1+1.4, 24.0+2.6 and
>60 days respectively. The mean survival of groups of host mice bearing EA/DR treated with 5mgkg-1 or
10mgkg-1 CsA simultaneously with daunorubicin for five days was also greater than 60 days. These
differences are highly significant.
The development of resistance to chemotherapeutic
drugs by neoplastic cells is a major obstacle to the
cure of many malignancies. Recent reports indicate
that it is possible to reverse resistance to vincristine
and to daunorubicin in murine tumours in vivo by
use of verapamil hydrochloride, the calcium channel
blocking agent (Tsuruo et al., 1981; Slater et al.,
1982; Xkovsgaard et al., 1984). The use of
verapamil in patients with malignancy has,
however, been limited by high concentration
requirements (Kessel & Wilberding, 1985a). We
now describe complete reversal of daunorubicin
resistance in daunorubicin resistant Ehrlich ascites
carcinoma by cyclosporin A used in doses
previously employed in humans.
Materials and methods
Tumour lines and treatment regimens
Ehrlich ascites carcinoma (EA) was maintained as
an ascitic tumour in BALB/c mice. A daunorubicin-
resistant subline was developed by sequential transfer
of EA cells to subsequent generations of host mice
with continuous daunorubicin treatment as pre-
viously described (Slater et al., 1982). For current
studies, the daunorubicin treatment regimen con-
sists of 0.3mgkg-' daunorubicin i.p. daily for five
doses, starting 24h after the inoculation of 0.2ml,
i.p. of undiluted malignant ascites harvested from
preterminal animals. CsA (Sandimmune I.V.,
Sandoz LTD) is given i.p. either alone or
simultaneously with daunorubicin at the doses
indicated.
Daunorubicin inhibition of[3H]-thymidine
incorporation
Nucleotide incorporation studies were performed by
the following method as previously described
(Slater et al., 1982). Cells were counted on a
haemocytometer using dye exclusion, washed and
resuspended in RPMI 1640 at a concentration of
2.5 x 106 ml- 1. Cell aliquots of 1.6ml were incu-
bated with 0.2ml daunorubicin HCI (final concen-
tration 0-12pgml-1) and 0.2ml cyclosporin A
(final concentration 0-13.2pgml-1) for 1 h in a
37°C water bath, washed twice and resuspended in
1.8ml RPMI. Triplicate 180p1 aliquots were placed
into microtiter plates and incubated with 20 l [3H]-
thymidine (sp. act. 24Cimmol-1, final concen-
tration 1iCiml-1) for Ih at 37°C in 5% CO2.
Samples were collected on glass fibre filters with a
Titertek multiple automated sample harvester unit
employing a deionized water wash. The filters were
dried and counted in a PPO/POPOP/toluene liquid
scintillation system. Results are expressed as a
comparison of [3H]-thymidine c.p.m. in dauno-
rubicin containing cultures to [3H]-thymidine c.p.m.
of the respective control in saline alone or CsA
alone. [3H]-thymidine incorporation of CsA alone
was greater than 85% of the saline control. The
daunorubicin ICSO is defined as that concentration
The Macmillan Press Ltd., 1986
Correspondence: L.M. Slater.
Received 17 February 1986; and in revised form 14 April
1986.236 L.M. SLATER et al.
of daunorubicin required to inhibit 50% of [3H]-
thymidine incorporation.
Results
Figure 1 compares the effects of3.3 and 13.2MgmlP
concentrations of CsA on daunorubicin inhibition
of DNA synthesis in daunorubicin sensitive and
daunorubicin resistant Ehrlich ascites carcinoma in
vitro. This figure is representative of three similar
experiments in which the daunorubicin IC50±s.d. for
drug sensitive EA was 2.8+0.72ugml -1. The dauno-
rubicin ICSO value of 6.7+1.15 for daunorubicin
resistant EA was reduced to 2.8+0.52pgmlml by
3.3igmlP-1 CsA (P<0.05) and to 2.1+0.10 by
13.2 igmlPl CsA (P<0.05). Table I compares the
in vivo effects of varied total doses of CsA
combined with daunorubicin on the survival of host
mice bearing daunorubicin resistant EA. Dauno-
rubicin alone and CsA alone failed to produce 60 day
survivors. However, the addition of CsA to dauno-
rubicin at the first three CsA doses studied resulted
in 60 day survival of all animals and over 50 day
survival of host ihice treated with daunorubicin
combined witheither 12.5mgkg- or 5mgkg- CsA.
The data presented are complied from four similar
in vivo experiments using the EA/DR subline.
Results expressed in (e)-(h) represent a single
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simultaneously performed experiment. Results (i)-
(1) represent three separate experiments each with a
simultaneously performed daunorubicin control
treatment arm for which the mean survival times
were 22.0+1.2, 21.8+1.0 and 23.1+7.3 days
respectively, all without 60 day survivors. Since
these values are essentially the same as that given in
(g), all combined CsA-daunorubicin treatments are
compared to 21.1+1.4 days in order to simplify the
tabular presentation.
Discussion
Our studies show that CsA alters the daunorubicin
inhibition of DNA synthesis in daunorubicin
resistant Ehrlich ascites carcinoma. The concen-
tration of daunorubicin required to inhibit 50% of
DNA synthesis in daunorubicin-sensitive tumour is
approximately one half the concentration required
to inhibit an equivalent amount of DNA synthesis
in the daunorubicin-resistant variant (P<0.05). The
addition of CsA to daunorubicin shifts the dauno-
rubicin ICSO of thymidine incorporation of EA/DR
cells to levels that are characteristic of the drug
sensitive tumour. Although the thymidine inhibition
assay may not directly reflect cellular viability, we
have previously found it to correlate well with in
vivo response (Slater et al., 1982). In vivo, the
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Figure 1 CsA effects on daunorubicin IC50 values in daunorubicin sensitive (a) and daunorubicin resistant
(b) Ehrlich ascites carcinoma (EA). Cells were washed and resuspended in RPMI 1640 at a concentration of
2.5 x l06ml-1. Cell aliquots of 1.6ml were incubated with 0.2ml daunorubicin HCI (final concentration
0-12jgml-1) and 0.2ml cyclosporin A at a final concentration of 0 (0--), 3.3pigml-1 (m-m), and
13.2.ugml-1 (x-x) for 1h at 37°C, washed twice and resuspended in 1.8ml RPMI. Other details as in
Materials and methods. Values are plotted as percent inhibition of [3H]-thymidine incorporation compared to
control in the absence ofdaunorubicin.CORRECTION OF DAUNORUBICIN RESISTANCE BY CYCLOSPORIN A 237
Table I Cyclosporin A reversal ofdaunorubicin resistance in vivo.
Mean survival+s.d. Long survivors
Tumour line Drug regimen (days) (60 days) Chi square P
(a) EA/DS 18.4+0.6 0/5
(b) EA/DS CsA (80mgkg1) 24.1+0.7 0/10
(c) EA/DS Daunorubicin >60 10/10
(d) EA/DS Daunorubicin
CsA (80mgkg-1) >60 9g/l0
(e) EA/DR 19.0+1.0 0/5
(f) EA/DR CsA (80mgkg1) 24.0+2.6 0/10
(g) EA/DR Daunorubicin 21.1+2.6 0/10 20 vs (c) <0.001
(h) EA/DR Daunorubicin 20 vs (g) <0.001
CsA (80mgkg') >60 10/10 0 vs (c), 1.1 vs (d) >0.1
(i) ES/DR Daunorubicin 20 vs (g) <0.001
CsA (50mgkg-1) >60 10/10 0 vs (c), 1.1 vs (d) >0.1
(j) EA/DR Daunorubicin 20 vs (g) <0.001
CsA (25mgkg-1) >60 10/10 0 vs (c), 1.1 vs (d) >0.1
(k) EA/DR Daunorubicin 8.5 vs (g) <0.01
CsA (12.5mgkg1) 53.9+9.1b 6/10 5 vs (c), 3 vs (d) <0.02, <0.05
(1) EA/DR Daunorubicin 5 vs (g), 6.4 vs (d) <0.02
CsA (Smgkg-') 51.2+9.8b 4/10 8.5 vs (c) <0.01
EA/DS and EA/DR signify daunorubicin sensitive and resistant tumour lines, respectively. The treatment regimen
consists of daunorubicin 0.3mgkg- i.p. daily for five doses, starting 24h after the inoculation of 0.2ml i.p. of undiluted
malignant ascites harvested from preterminal BALB/c host mice. Total CsA treatment regimens given either alone or
simultaneously with daunorubicin in five divided doses are indicated; aIndicates the death of one animal in this group at
day 5 with diarrhoea. Chi square values compare the frequency of 60 day survival between the indicated groups; bIndicates
mean survival calculated using 60 day survival for each long survivor.
addition of CsA to daunorubicin in the treatment
of EA/DR bearing host mice also restores responses
to daunorubicin. When CsA is added to the dauno-
rubicin treatment of the resistant subline, the
reduced survival of host mice bearing daunorubicin
resistant EA treated with daunorubicin alone
returns to the survival characteristic of host mice
bearing daunorubicin sensitive EA.
Although the doses of CsA used in these in vivo
murine studies are similar to those previously
employed in humans (Biggs et al., 1983; Kennedy et
al., 1985) the use of intraperitoneal CsA in the
treatment of an ascitic tumour would favour high
local drug concentrations. It is of interest, however,
that tissue levels of CsA determined at postmortem
examination in patients maintained on CsA for
over one week until death range from several
hundred to over 7000ngg-1 of tissue wet weight
(Ried et al., 1983). These values compare
favourably to the 3300ngml-' CsA concentration
demonstrated to reverse daunorubicin resistance in
EA in vitro. Although the efficacy of CsA in
reversing drug resistance of human tumours in vivo
has not yet been demonstrated, we do note
important in vitro activity of CsA in daunorubicin
resistant human acute lymphatic leukaemia. CsA
completely reverses 50-fold primary resistance to
vincristine and 5-fold cross resistance to dauno-
rubicin in a pleiotropic drug resistant subline of
GM3639 human T cell acute lymphatic leukaemia -
Human Genetic Mutant Cell Repository, Camden,
New Jersey (Slater et al., 1986).
The mechanism by which CsA restores responses
to daunorubicin and to vincristine is unclear, but
may relate to its ability to inhibit calmodulin
(Colombani et al., 1985). Verapamil and calmodulin
inhibitors have been shown to correct the enhanced
active efflux of vinca alkaloids and anthracycline
antibiotics characteristic of drug resistant tumour
cells resulting in increased cellular drug retention
(Tsuruo et al., 1981; 1982). However, Kessel &
Corbett (1985) were unable to demonstrate a
correlation between adriamycin uptake and adria-
mycin resistance in murine solid tumours rendered
resistant to adriamycin by in vivo drug exposure.
We were similarly unable to detect significant
differences in daunorubicin uptake between our
daunorubicin-sensitive and daunorubicin-resistant
Ehrlich ascites carcinoma subline and drug
sensitive versus pleiotropic drug resistant human
acute lymphatic leukaemia subline (Slater et al.,
1986), suggesting that the mechanism of CsA effect
lies beyond the modification of drug transport.
Since the acquisition of equimolar concentrations
of anthracyclines by anthracycline resistant com-
pared to anthracycline sensitive tumour cells fails238 L.M. SLATER et al.
to restore equivalent cytotoxic drug effect to these
cells (Kessel & Wilberding, 1985b; Sikic et al.,
1985), the mechanism by which calcium channel
blocking agents and calmodulin inhibitors restore
drug sensitivity must extend beyond drug retention.
It has been shown that adriamycin is cytotoxic
when the drug is bound to polygluteraldehyde micro-
spheres or to agarose, which prevents its entry
into tumour cells and suggests that cytotoxicity
occurs as a cell surface phenomenon (Tritton &
Yee, 1982; Rogers et al., 1983). The mechanism of
anthracycline antibiotic resistance relates to the cell
membrane as well, since recent reports show that
pleiotropic drug resistant cells possess characteristic
cell membrane glycoprotein alterations in addition
to the enhanced active drug efflux described above
(Kartner et al., 1983a,b).
The studies of LeGrue et al. (1983) raise the
possibility that CsA might function in the plasma
membrane in a manner similar to that of lipid
soluble anaesthetics by increasing lipid fluidity and
uncoupling electrochemical action potentials. Since
drug retention alone cannot account for the effects
of calcium channel blocking drugs and calmodulin
inhibitors on vinca alkaloid and anthracycline
antibiotics in pleiotropic drug resistant cells, it has
been suggested that these agents, and it now
appears that CsA, may enhance intracellular drug
binding or promote favourable chemotherapeutic
drug interactions at the membrane level (Beck,
1983; Kessel & Wilberding, 1985b).
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